Osteoporosis International

, Volume 19, Issue 9, pp 1247–1250

Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science

  • J. Compston
  • D. M. Reid
  • J. Boisdron
  • M.-L. Brandi
  • N. Burlet
  • D. Cahall
  • P. D. Delmas
  • W. Dere
  • J.-P. Devogelaer
  • L. A. Fitzpatrick
  • B. Flamion
  • N. Goel
  • S. Korte
  • A. Laslop
  • B. Mitlak
  • S. Ormarsdottir
  • J. Ringe
  • R. Rizzoli
  • Y. Tsouderos
  • T. Van Staa
  • J.-Y. Reginster
Consensus Statement

DOI: 10.1007/s00198-008-0670-7

Cite this article as:
Compston, J., Reid, D.M., Boisdron, J. et al. Osteoporos Int (2008) 19: 1247. doi:10.1007/s00198-008-0670-7

Keywords

Bone mineral densityBridging studyGlucocorticoid-induced osteoporosisMenPhase III studiesPostmenopausal women

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2008

Authors and Affiliations

  • J. Compston
    • 1
  • D. M. Reid
    • 2
  • J. Boisdron
    • 3
  • M.-L. Brandi
    • 4
  • N. Burlet
    • 5
  • D. Cahall
    • 6
  • P. D. Delmas
    • 7
  • W. Dere
    • 8
  • J.-P. Devogelaer
    • 9
  • L. A. Fitzpatrick
    • 10
  • B. Flamion
    • 11
  • N. Goel
    • 12
  • S. Korte
    • 13
  • A. Laslop
    • 14
  • B. Mitlak
    • 15
  • S. Ormarsdottir
    • 16
  • J. Ringe
    • 17
  • R. Rizzoli
    • 18
  • Y. Tsouderos
    • 19
  • T. Van Staa
    • 20
  • J.-Y. Reginster
    • 21
  1. 1.Department of MedicineUniversity of Cambridge School of Clinical MedicineCambridgeUK
  2. 2.University of Aberdeen Medical SchoolAberdeenUK
  3. 3.Hoffman-La Roche LtdBasleSwitzerland
  4. 4.Metabolic Bone Unit, Laboratory of Molecular Genetics, Department of Internal MedicineUniversity of FlorenceFlorenceItaly
  5. 5.International Osteoporosis FoundationNyonSwitzerland
  6. 6.Sanofi-AventisCincinnatiUSA
  7. 7.Department of MedicineUniversity of Lyon and INSERM Research Unit 831LyonFrance
  8. 8.AmgenThousand OaksUSA
  9. 9.The Arthritis UnitUniversité Catholique de LouvainBrusselsBelgium
  10. 10.Medicines Disease CenterGlaxoSmithKlineKing of PrussiaUSA
  11. 11.Laboratory of Physiology and PharmacologyUniversity of NamurNamurBelgium
  12. 12.Clinical Development, UCB Inc.SmyrnaUSA
  13. 13.Novartis PharmaAGSwitzerland
  14. 14.AGES PharmMedViennaAustria
  15. 15.Lilly Research LaboratoriesEli Lilly and CompanyIndianapolisUSA
  16. 16.Icelandic Medicines Control AgencySeltjarnarnesIceland
  17. 17.West German Osteoporosis Center (WOZ) and Med. Clinic 4 at Klinikum LeverkusenUniverity of CologneCologneGermany
  18. 18.Division of Bone Diseases, WHO Collaborating Centre for Osteoporosis Prevention, Department of Rehabilitation and GeriatricsGeneva University Hospitals and Faculty of MedicineGenevaSwitzerland
  19. 19.Institut de Recherches Internationales ServierCourbevoieFrance
  20. 20.General Practice Research DatabaseMedicines and Healthcare Products Regulatory AgencyLondonUK
  21. 21.Department of Public Health SciencesUniversity of Liège, Liège, Belgium, Chairman GREESLiègeBelgium